Viagen Pets charges $50,000 per cat or dog clone via somatic cell nuclear transfer

Loyal advances three canine longevity candidates. One metabolic health compound now runs in a 1,300-dog US trial. Parallel programs target age-related disease pathways in dogs and cats. Primary endpoints track lifespan extension and disease incidence against breed-matched controls.

Viagen executes somatic cell nuclear transfer from preserved fibroblast lines into enucleated oocytes, followed by surrogate implantation. Published outcomes show 5-20% live birth rates per transfer cycle across species. Resulting animals are genetic twins yet display measurable epigenetic and behavioral divergence by 12 months. Alcor reports 200+ pet cases stored at liquid nitrogen temperatures, including the first sugar glider announced in 2026.

Cloning success depends on oocyte quality and mitochondrial carry-over, not on behavioral replication. Cryonic revival remains contingent on future molecular repair technologies that lack current experimental validation in mammals. Regulatory classification of longevity drugs for companion animals requires safety data packages equivalent to those for food-producing species.

Next milestones include Loyal's interim trial readout in 2027 and any FDA-CVM conditional approval decision. Cryonics facilities continue incremental case growth without published revival protocols.